Tixupharma
Regenerative Therapeutics
Discovery platform to develop metabolic therapeutics to treat chronic and/or aging diseases.
About Us
Tixupharma is an innovative medical device company based in Milan, established in 2013 as academic spin-out and consolidated in 2019 to pioneer untapped regenerative pathways in age-related and traumatic diseases.
The team and partners of Tixupharma combines multidisciplinary expertise including preclinical models, clinical trials, regulatory and IP knowledge, industrial operations and business development.
Mission
Worldwide, millions of people suffer from unmet degenerative diseases requiring effective therapeutics.
Our mission is to develop first-in-class therapies to treat such diseases by leveraging mechanotransduction driving-forces starting from the unmet women's healthcare need.
Therapeutics pipeline
We’re building a pipeline on the understanding to exploit non-pharmacologic, autocrine signaling pathways, and to advance our core therapeutics for unmet or undeserved medical needs. Through medical device strategy, we wish to evolve into regenerative medicine with highest unmet needs and opportunities.
Our therapeutics entail female genitourinary disorders. Other initiatives were withdrawn due to incurrent financial instability.